Full-Time
Senior National Director
Strategic Accounts, Rare Neurology
Otsuka Pharmaceutical
1,001-5,000 employees
Global pharma maker of Abilify
Compensation Overview
$215.4k - $322k/yr
Remote in USA
Remote
Bachelor's, Master's
 Sales & Account Management (1) |
|---|
Get referred to Otsuka Pharmaceutical
See people who can refer or advise you
- A bachelor's degree is required.
- At least 12 years of progressive experience in pharmaceutical or biotechnology sales leadership is required.
- At least 7 years of leadership experience is required.
- Proven experience launching products for rare or ultra-rare diseases is required.
- Demonstrated success leading high-stakes launches with urgency and accountability is required.
- Proven success building and leading high-performing sales or account management teams is required.
- Experience in strategic account management within complex healthcare ecosystems, including centers of excellence, is required.
- Strong working knowledge of complex reimbursement landscapes is required.
- Demonstrated ability to drive sales performance and deliver results, think strategically and execute tactically, and operate effectively in ambiguous and fast-changing environments is required.
- Strong clinical acumen and the ability to navigate complex treatment pathways and logistics are required.
- Strong organizational, prioritization, and time management skills are required.
- Strong coaching, influencing, and leadership capabilities are required.
- High emotional intelligence and the ability to lead through change are required.
- A deep understanding of industry compliance, the regulatory environment, and standards of practice is required.
- Strong alignment with a patient-centric, values-driven culture is required.
- Recruit, hire, onboard, and develop a team of approximately 10 Account Managers, establishing best-in-class account management capability.
- Act as a player-coach by providing hands-on coaching in the field to elevate team performance and impact.
- Build a high-performance, high-accountability culture grounded in Otsuka values.
- Drive engagement, retention, and talent development, including succession planning and capability building.
- Establish clear goals, performance metrics, and operating cadence to ensure consistent execution.
- Lead the development and execution of strategic account plans across key centers of excellence.
- Ensure Account Managers effectively navigate complex stakeholder ecosystems, including healthcare professionals, multidisciplinary care teams, hospital pharmacy, and financial decision makers within hospital systems, including C-suite members.
- Personally engage with top-tier accounts to model best-in-class partnership behaviors.
- Serve as a key member of the commercial leadership team, shaping national sales strategy and execution priorities.
- Own and drive performance across sales targets and account performance metrics.
- Translate national strategy into actionable, field-level, center-specific execution plans.
- Ensure agility and rapidly recalibrate strategies in response to market dynamics.
- Navigate and coach teams through complex treatment logistics, including site-of-care considerations, patient onboarding, and therapy initiation barriers.
- Partner closely with Market Access and Patient Support to compliantly remove barriers to therapy.
- Ensure the team demonstrates understanding of complex reimbursement dynamics and specialty pharmacy and distribution networks.
- Maintain a strong clinical understanding of the disease state, treatment paradigm, and clinical profile.
- Enable the team to confidently engage in scientifically grounded, compliant discussions with healthcare stakeholders.
- Support execution in complex treatment pathways, including rare and specialty disease dynamics.
- Ensure alignment of account strategy, customer engagement, and patient support initiatives.
- Provide field insights to inform brand strategy, access strategy, and lifecycle planning.
- Compliantly align cross-functional stakeholders behind a shared vision, breaking down silos and fostering collaboration to bring the full power of the organization to customers.
- Lead the team through change, ambiguity, and new ways of working, including evolving engagement models.
- Identify and implement new approaches to account engagement and performance optimization.
- An advanced degree is desirable.
Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Tokyo, Japan
Founded
1921
Get referred to Otsuka Pharmaceutical
See people who can refer or advise you
Simplify's Take
What believers are saying
- Otsuka closed Transcend in June 2026, expanding psychiatry beyond Abilify dependence.
- DAWNZERA gained EU authorization in January 2026, opening paid sales across 27 countries.
- Paradise uRDN and CART BP pro broaden Japan's hypertension platform and device distribution.
What critics are saying
- SIMTRIYO waits on DEA scheduling, delaying revenue until late 2026.
- VOYXACT's accelerated approval depends on confirmatory kidney-outcome data; failure risks withdrawal.
- Transcend's TSND-201 PTSD program remains clinical-stage, risking a $1.225 billion write-down.
What makes Otsuka Pharmaceutical unique
- Otsuka pairs CNS, nephrology, and device assets across Japan, US, and Europe.
- SIMTRIYO gives Otsuka a first-in-class ADHD stimulant franchise after July 2026 FDA approval.
- DAWNZERA and VOYXACT anchor rare-disease pipelines with global reimbursement and accelerated paths.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Tuition Reimbursement
Student Loan Assistance
Paid Holidays
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.
SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.
Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.
Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.
Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.